[Yu Jin-hee, Edaily Reporter] As glucagon-like peptide-1 (GLP-1) therapies for obesity and diabetes establish themselves as a major trend in the global pharmaceutical and biotech sectors, strong buying momentum is driving interest in domestic companies with relevant drug pipelines and manufacturing infrastructure.

On the 16th, the South Korean market focused on companies with tangible catalysts—beyond fleeting thematic hype—including global regulatory manufacturing approvals, selection for national R&D projects, and growing traction in medical e-commerce distribution, propelling them to the top of the daily gainers list.

Osong Facility Passes U.S. and European Audits… Quratis Launches Obesity CDMO Initiative

According to financial data provider KG Zeroin MP DOCTOR, the biotech stocks that made it into the top 20 gainers across the domestic market that day were Quratis (348080), MFC (432980), and Bluemtec (439580).

Quratis closed at its 30.00% daily upper limit of 3,705 KRW. MFC also hit the ceiling, surging 29.96% to 3,145 KRW. Medical e-commerce distributor Bluemtec rallied 14.54% to close at 2,600 KRW.

Market experts note that growing manufacturing bottlenecks and intensifying demand for convenient drug administration routes are creating structural tailwinds for contract development and manufacturing organizations (CDMOs), oral formulation specialists, and specialized distribution networks.

Analysts caution, however, that because these rallying stocks trade in the 2,000 to 3,000 KRW low-price bracket, investors must remain vigilant against heightened volatility driven by short-term speculative capital inflows. Market participants are advised to scrutinize fundamental metrics, including underlying balance sheet health and actual cash-generation capabilities.

Quratis surged to the daily limit shortly after the opening bell, driven by manufacturing audit certifications from U.S. health authorities and expectations surrounding global drug manufacturing contracts for obesity and metabolic diseases.

The company received an on-site audit certificate for its Osong Bio Plant from the Division of AIDS within the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. National Institutes of Health (NIH).

The audit covered sterile injectable manufacturing and quality standards, including Quratis’ tuberculosis vaccine candidate QTP101. The company is actively negotiating supply agreements to provide clinical-stage vaccines and adjuvants for trials across the United States and Europe.

Quratis’s Osong production hub has systematically secured endorsements from leading global regulatory agencies. Following Current Good Manufacturing Practice (cGMP) clinical supply approval from the U.S. Food and Drug Administration (FDA) in July of last year, the facility passed an on-site audit by an EU Good Manufacturing Practice (EU-GMP) Qualified Person (QP).

Building on these credentials, Quratis partnered with Inventage Lab, a company specializing in long-acting injectable platforms, to launch biomanufacturing operations. The two companies finalized supply pricing for clinical drug candidates across major pipelines—including treatments for obesity, diabetes, and dementia—and began manufacturing clinical batches. European pharmaceutical companies and domestic biotech firms have also conducted on-site facility inspections, with follow-up discussions regarding contract manufacturing currently underway.

A previous clinical supply contract with a U.S. biotech firm to provide an adjuvant for an HIV vaccine program further strengthens Quratis’s operational standing. The company has established a track record in manufacturing by supplying finished batches to clinical programs supported by U.S. health agencies.

Market observers view Quratis’s strategy of capitalizing on global shortages of injectable supplies—rather than relying solely on high-risk in-house discovery—as a calculated move. Expectations are growing that rising factory utilization rates, achieved under validated Western regulatory standards, could lift the company out of chronic operating losses and toward a mid- to long-term turnaround.

“Passing rigorous audits by leading global agencies validates our manufacturing credibility on the international stage,” a Quratis official stated. “We intend to expand contract manufacturing orders across high-value obesity and metabolic disease treatments to establish a firm foundation for operational earnings.”

Leading 7.1 Billion KRW Oral Insulin Project… MFC Deploys AI Formulation Engine

MFC, a specialist in high-value active pharmaceutical ingredients (APIs), hit its daily price limit after being selected as the lead research organization for a government-sponsored initiative to develop next-generation oral insulin.

The Ministry of Trade, Industry and Energy selected MFC to spearhead the personalized diagnostic and therapeutic products division under the Bio Industry Technology Development Project, the company announced on the 16th.

The initiative has a total budget of approximately 7.1 billion KRW, including 4.8 billion KRW in government grants. Over the next 54 months through December 2030, MFC will lead the development of an oral insulin finished drug using artificial intelligence (AI) and continuous manufacturing processes.

While daily subcutaneous insulin injections suffer from poor patient compliance, developing an ingestible pill has long presented a scientific challenge because therapeutic proteins break down rapidly due to digestive enzymes in the gastrointestinal tract and exhibit low absorption across intestinal barriers.

MFC is partnering with Kookmin University to apply specialized peptide stabilization and permeation-enhancing technologies designed to prevent gastrointestinal degradation. The Dongguk University Industry-Academic Cooperation Foundation is overseeing non-clinical pharmacokinetic and bioavailability evaluations.

By leveraging data-driven predictive AI models, the consortium aims to reduce candidate screening and manufacturing timeline milestones by up to 50%. MFC aims to complete non-clinical efficacy and safety evaluations by 2030, paving the way for Phase 1 clinical trials and global out-licensing deals.

MFC holds a proprietary position as the first company in the world to crystallize TBFA—an essential liquid intermediate for cholesterol-lowering statin drugs—into a solid form. Moving beyond conventional generic ingredients, the company launched the Ilaprazole API—a proton pump inhibitor (PPI) for gastroesophageal reflux disease—and plans to roll out high-margin generic and reformulated API lines, including the nonsteroidal anti-inflammatory ingredient Pelubiprofen.

Global commercialization is also progressing. MFC is conducting process validation batches to supply cholesterol drug APIs to a leading Japanese partner, while also engaging in ongoing CMO discussions with domestic and multinational pharmaceutical companies.

“We will complete platform technologies that transform injectable diabetes treatments into daily oral tablets,” an MFC official commented. “Leveraging our high-precision AI formulation capabilities, we will accelerate our evolution into an advanced digital pharmaceutical platform company.”

Capitalizing on Wegovy Distribution Volumes… Bluemtec Accelerates Toward Profitability

Bluemtec, the leading domestic pharmaceutical e-commerce platform, staged a double-digit rally driven by surging hospital distribution volumes of GLP-1 weight-loss medications, coupled with an expanding, high-margin medical aesthetics lineup. Operating its specialized medical portal BluePharmKorea, Bluemtec serves as a primary supply conduit across local South Korean clinics.

The company’s commercial growth accelerated as multinational blockbuster drugs, such as Novo Nordisk’s Wegovy, entered domestic clinic distribution networks. Industry estimates suggest that Bluemtec generated approximately 50 billion KRW in sales of obesity drugs alone last year.

Driven by these supply volumes, Bluemtec’s total annual revenue jumped 39% year-over-year to 185.7 billion KRW last year. Concurrently, operating losses narrowed by 71%, shrinking from 6.9 billion KRW to 2.0 billion KRW over the same period.

Bluemtec is transforming its network of more than 30,000 registered clinic accounts—initially engaged through high-demand therapeutics—into recurring buyers of profitable aesthetic products. By partnering with aesthetic manufacturers Medytox and Humedix, the platform has added botulinum toxin and hyaluronic acid (HA) dermal filler portfolios to its offerings.

The platform is increasing the size of clinic orders by distributing Medytox’s flagship Neuramis dermal filler line and submental fat-reducing injectables. Industry forecasts indicate that the global medical aesthetics market will exceed 200 trillion KRW by 2030.

Beyond physical drug logistics, Bluemtec is diversifying into management service organization (MSO) offerings. The company recently partnered with marketing specialists to launch targeted apartment elevator media advertising packages for neighborhood clinics, unlocking high-margin software and advertising revenue.

With monthly operations crossing the break-even point (BEP) thanks to overhead rationalization and a higher-margin product mix, analysts view an annual transition to profitability as increasingly viable.

“Building on the platform leverage demonstrated through obesity drug distribution, we are strengthening our supply of aesthetic solutions such as fillers and neurotoxins,” a Bluemtec official stated. “Our focus this year is on executing both top-line growth and structural efficiency to deliver record revenue and our first-ever annual operating profit.”

Rallying Micro-Cap Biotech Stocks… “Evaluate Cash Runway and Operational Stamina”

While market observers view the company’s alignment with global demand for obesity and metabolic treatments favorably, they caution against unchecked momentum chasing.

The sector frequently experiences sharp swings whenever major catalysts emerge. Small-cap stocks trading in the 2,000 to 3,000 KRW range remain vulnerable to extreme price volatility should institutional or foreign investors move to lock in gains amid thin liquidity.

“Commercializing obesity and diabetes initiatives into tangible operating profits requires clearing multiple validation hurdles, including production yield stability, regulatory clearances, and sustained prescription adherence,” noted BioBook CEO Hong Soon-jae. “Beyond scientific platforms, investors must carefully evaluate financial resilience—including cash reserves, debt obligations, and underlying core operating profitability—before deploying capital.”